A guide to diagnosis and treatment of Leigh syndrome

Fabian Baertling, Richard J. Rodenburg, Jörg Schaper, Jan A. Smeitink, Werner J.H. Koopman, Ertan Mayatepek, Eva Morava-Kozicz, Felix Distelmaier

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

Leigh syndrome is a devastating neurodegenerative disease, typically manifesting in infancy or early childhood. However, also late-onset cases have been reported. Since its first description by Denis Archibald Leigh in 1951, it has evolved from a postmortem diagnosis, strictly defined by histopathological observations, to a clinical entity with indicative laboratory and radiological findings. Hallmarks of the disease are symmetrical lesions in the basal ganglia or brain stem on MRI, and a clinical course with rapid deterioration of cognitive and motor functions. Examinations of fresh muscle tissue or cultured fibroblasts are important tools to establish a biochemical and genetic diagnosis. Numerous causative mutations in mitochondrial and nuclear genes, encoding components of the oxidative phosphorylation system have been described in the past years. Moreover, dysfunctions in pyruvate dehydrogenase complex or coenzyme Q10 metabolism may be associated with Leigh syndrome. To date, there is no cure for affected patients, and treatment options are mostly unsatisfactory. Here, we review the most important clinical aspects of Leigh syndrome, and discuss diagnostic steps as well as treatment options.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume85
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Leigh Disease
coenzyme Q10
Pyruvate Dehydrogenase Complex
Gene Components
Mitochondrial Genes
Oxidative Phosphorylation
Basal Ganglia
Neurodegenerative Diseases
Cognition
Brain Stem
Molecular Biology
Therapeutics
Fibroblasts
Muscles
Mutation

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Baertling, F., Rodenburg, R. J., Schaper, J., Smeitink, J. A., Koopman, W. J. H., Mayatepek, E., ... Distelmaier, F. (2014). A guide to diagnosis and treatment of Leigh syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 85(3), 257-265. https://doi.org/10.1136/jnnp-2012-304426

A guide to diagnosis and treatment of Leigh syndrome. / Baertling, Fabian; Rodenburg, Richard J.; Schaper, Jörg; Smeitink, Jan A.; Koopman, Werner J.H.; Mayatepek, Ertan; Morava-Kozicz, Eva; Distelmaier, Felix.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 85, No. 3, 01.01.2014, p. 257-265.

Research output: Contribution to journalReview article

Baertling, F, Rodenburg, RJ, Schaper, J, Smeitink, JA, Koopman, WJH, Mayatepek, E, Morava-Kozicz, E & Distelmaier, F 2014, 'A guide to diagnosis and treatment of Leigh syndrome', Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, no. 3, pp. 257-265. https://doi.org/10.1136/jnnp-2012-304426
Baertling F, Rodenburg RJ, Schaper J, Smeitink JA, Koopman WJH, Mayatepek E et al. A guide to diagnosis and treatment of Leigh syndrome. Journal of Neurology, Neurosurgery and Psychiatry. 2014 Jan 1;85(3):257-265. https://doi.org/10.1136/jnnp-2012-304426
Baertling, Fabian ; Rodenburg, Richard J. ; Schaper, Jörg ; Smeitink, Jan A. ; Koopman, Werner J.H. ; Mayatepek, Ertan ; Morava-Kozicz, Eva ; Distelmaier, Felix. / A guide to diagnosis and treatment of Leigh syndrome. In: Journal of Neurology, Neurosurgery and Psychiatry. 2014 ; Vol. 85, No. 3. pp. 257-265.
@article{f5befda675bb439db4548c9e08ae8184,
title = "A guide to diagnosis and treatment of Leigh syndrome",
abstract = "Leigh syndrome is a devastating neurodegenerative disease, typically manifesting in infancy or early childhood. However, also late-onset cases have been reported. Since its first description by Denis Archibald Leigh in 1951, it has evolved from a postmortem diagnosis, strictly defined by histopathological observations, to a clinical entity with indicative laboratory and radiological findings. Hallmarks of the disease are symmetrical lesions in the basal ganglia or brain stem on MRI, and a clinical course with rapid deterioration of cognitive and motor functions. Examinations of fresh muscle tissue or cultured fibroblasts are important tools to establish a biochemical and genetic diagnosis. Numerous causative mutations in mitochondrial and nuclear genes, encoding components of the oxidative phosphorylation system have been described in the past years. Moreover, dysfunctions in pyruvate dehydrogenase complex or coenzyme Q10 metabolism may be associated with Leigh syndrome. To date, there is no cure for affected patients, and treatment options are mostly unsatisfactory. Here, we review the most important clinical aspects of Leigh syndrome, and discuss diagnostic steps as well as treatment options.",
author = "Fabian Baertling and Rodenburg, {Richard J.} and J{\"o}rg Schaper and Smeitink, {Jan A.} and Koopman, {Werner J.H.} and Ertan Mayatepek and Eva Morava-Kozicz and Felix Distelmaier",
year = "2014",
month = "1",
day = "1",
doi = "10.1136/jnnp-2012-304426",
language = "English (US)",
volume = "85",
pages = "257--265",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - A guide to diagnosis and treatment of Leigh syndrome

AU - Baertling, Fabian

AU - Rodenburg, Richard J.

AU - Schaper, Jörg

AU - Smeitink, Jan A.

AU - Koopman, Werner J.H.

AU - Mayatepek, Ertan

AU - Morava-Kozicz, Eva

AU - Distelmaier, Felix

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Leigh syndrome is a devastating neurodegenerative disease, typically manifesting in infancy or early childhood. However, also late-onset cases have been reported. Since its first description by Denis Archibald Leigh in 1951, it has evolved from a postmortem diagnosis, strictly defined by histopathological observations, to a clinical entity with indicative laboratory and radiological findings. Hallmarks of the disease are symmetrical lesions in the basal ganglia or brain stem on MRI, and a clinical course with rapid deterioration of cognitive and motor functions. Examinations of fresh muscle tissue or cultured fibroblasts are important tools to establish a biochemical and genetic diagnosis. Numerous causative mutations in mitochondrial and nuclear genes, encoding components of the oxidative phosphorylation system have been described in the past years. Moreover, dysfunctions in pyruvate dehydrogenase complex or coenzyme Q10 metabolism may be associated with Leigh syndrome. To date, there is no cure for affected patients, and treatment options are mostly unsatisfactory. Here, we review the most important clinical aspects of Leigh syndrome, and discuss diagnostic steps as well as treatment options.

AB - Leigh syndrome is a devastating neurodegenerative disease, typically manifesting in infancy or early childhood. However, also late-onset cases have been reported. Since its first description by Denis Archibald Leigh in 1951, it has evolved from a postmortem diagnosis, strictly defined by histopathological observations, to a clinical entity with indicative laboratory and radiological findings. Hallmarks of the disease are symmetrical lesions in the basal ganglia or brain stem on MRI, and a clinical course with rapid deterioration of cognitive and motor functions. Examinations of fresh muscle tissue or cultured fibroblasts are important tools to establish a biochemical and genetic diagnosis. Numerous causative mutations in mitochondrial and nuclear genes, encoding components of the oxidative phosphorylation system have been described in the past years. Moreover, dysfunctions in pyruvate dehydrogenase complex or coenzyme Q10 metabolism may be associated with Leigh syndrome. To date, there is no cure for affected patients, and treatment options are mostly unsatisfactory. Here, we review the most important clinical aspects of Leigh syndrome, and discuss diagnostic steps as well as treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84896722661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896722661&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2012-304426

DO - 10.1136/jnnp-2012-304426

M3 - Review article

C2 - 23772060

AN - SCOPUS:84896722661

VL - 85

SP - 257

EP - 265

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 3

ER -